Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
When all this happens, it should be a different story.
It should not be a lot as nothing is happening (hope they got a fixed price )
Wonder what their cash burn rate is so far this year?
Wonder how the Phase 2 Covid trial start date is getting on…Imminent hopefully
Wonder if they sent a sample to UK-CTAP to analyse and try it?
Wonder how the MS patient is getting on??
I wonder when we will hear about what's happening with the Takanawa strategic initiative in relation to Milciclib in Asia. The RNS announcing the initiative was released on 5 May so we are getting on for three months now. Perhaps it's unrealistic to expect news for another few months yet.
The price spiked because lots of less-than-savvy robinhood users mistakenly bought shares in TLSA thinking it was TSLA. it may well be that the ADR news brought our ticker into public view so it may well have been the root cause. They were sold reasonably quickly once the mistake was realised, hence the sharp up and down to the peak.
https://markets.businessinsider.com/news/stocks/tesla-stock-tiziana-ticker-confusion-potentially-benefiting-biotech-company-mixup-2020-7
However you look at it it was a false spike and really oughtn't be referred to as the share's high spot, even though technically it was.
Denny, the high price was more to do with the ADR ratio change from 5:1 to 2:1 causing confusion over the pond IMO.
Although I do agree slightly, there were some yanks and there still are some yanks mixing up TLSA and TSLA but I’m not sure it was enough to really move the SP.
I believe the herd mentality also came into play a year ago which resulted in a shortage of stock for MM’s, thus driving the price up.
Hopefully we will see that herd mentality again in the future but excitement is needed around the stock which is lacking at the moment.
It isn't down from 300, that was a false extreme spike caused by the robinhood users in the US confusing the Tesla ticker (TSLA) with the US ADR ticker (TLSA).
That's not to say TILS won't reach 300p or more at some point, but I would suggest the more realistic top price to comare it to is somewhere around 200, if you exclude that spike
I remember the 150p min raise price being stated last time they raised
It will come good here. I can feel it brewing lol
jh2704: My view is that we will run out of money in 12 to 18 months.
Tils state they are funded through 2022, but good practice is to have funds to see you through the next 12 months minimum. I imagine they will look to raise funds early next year after successful Foralumab trials to achieve POC .
They have ADR's on the shelf for up to $250m ready to go, there was talk of a price of £1.50 as the issue price, but I cannot find anything stating this. The SEC filing was late January 21.
BB
ROCKZ
Let's hope you're right.
@jh2704
Yes I think you are on the right lines.
Roker, er disagree. Look at the valuations of similar companies. ITEOS has been flirting around the $1billion MCAP in recent months during a period where BioPharma stocks are pretty flat.
PRVB were comfortably over a $1.2billion MCAP whilst in Phase 3 trials.
If Foralumab is as good as what they think, maybe expect a JV or licensing deal similar to ITOS but I don’t think he’ll sell it outright for $1 billion.
If he does, happy days, I’m quids in but I think he’s built a team around him with a proven track record of delivery therapeutics and some of those guys will want to see it through along with the kudos that brings.
Roker. My view is that we will run out of money in 12 to 18 months. The last set of iis didn’t do great in the last placing. So iis will be difficult to attract in any new placing and will drive a hard bargain. So imho the bod have to sell before any need for placing becomes imminent
So sooner rather than later logic tells me we will be sold
Do you concur roker? Or have I drunk 1 too many yet again?
@ROCKZ
Errrr....I think he might.
204p would be a cheeky bid. I doubt GC would even entertain a lowball offer like that but it would be a case of ‘the first shot across the bow’.
This could then but other interested parties to the table, hopefully resulting in a bidding war.
He won’t sell for less than $1billion IMO
I've just been looking back at some of my posts about Accustem last year. This was from 22 September 2020. How disappointing. Come on GC, get us some real liquidity!
"Something that is getting under my skin just now is a concern I mentioned earlier today, that I dislike the fact that the demerger is not conditional on the admission of the Accustem shares ie. the circular clearly points to a gap between demerger on 30 October and admission (listing) of the Accustem shares. So for a while (up to two months in the circular) we could have no liquidity in our Accustem shares. Moreover there is no obligation on the board to ever do the listing, although I have to believe it intends to. But is there a circumstance where admission might never happen and we get stuck with unlisted, illiquid stock in Accustem?"
@jh2704
So do I.
It was a rumour the 300p but certainly believable. The bod are very quiet. Something is happening I do believe
But then again I want to believe
Down from 300p, could a cheeky bid come in.
After 11th Aug it drops to 204p.
I guess they'd wait a few days to save £40m. Didn't GC turn down £3 , or was it just a rumour? But that did include Accustem, whatever the value of that is???
BB